“Biopharmaceutical researchers throughout Japan and Asia are eager to learn how COA data can help them meet their clinical objectives,” said Akiyoshi Uchiyama, M.D., Ph.D.,
Tokyo, Japan (PRWEB) September 10, 2013
ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today opened registration for its PROFICIENCY conference in Tokyo, Japan. The conference, which takes place October 24, 2013 at the Hotel Okura Tokyo, focuses on developing, implementing, and justifying effective strategies for collecting high quality Clinical Outcome Assessment (COA) data in clinical research.
“Biopharmaceutical researchers throughout Japan and Asia are eager to learn how COA data can help them meet their clinical objectives,” said Akiyoshi Uchiyama, M.D., Ph.D., former board member and deputy director of GlaxoSmithKline Japan. “This PROFICIENCY conference comes at a time of great interest in this area and should prove very valuable to those who attend.”
The one-day conference is designed to answer the questions that biopharmaceutical researchers have about using COA and electronic COA (eCOA) in Japanese-based clinical trials. A faculty of international regulators, biopharmaceutical professionals and industry experts will present case studies and strategic/tactical information related to:
- The current regulatory landscape for COA and eCOA
- The effective use of electronic Patient Reported Outcomes (ePRO) in worldwide (including Asian) clinical trials
- Addressing the social problem of suicide and assessing Suicidal Ideation & Behavior (SIB) in clinical trials for new drug development
“The Tokyo PROFICIENCY conference offers Japanese researchers an opportunity to network with leading industry and regulatory professionals while advancing their knowledge of the strategic and tactical issues pertaining to patient safety and efficacy data collection in their clinical trials,” said Dr. Jean Paty, ERT’s Chief Regulatory and Scientific Advisor, Outcomes. “We’re very excited to address these important topics and to extend this educational opportunity to our Japanese colleagues.”
For more information and to register for the meeting, please visit http://www.ertjapan.jp.
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COA) – which includes patient, clinician, and observer reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labeling, and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.